The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Beta Bionics Inc (NASDAQ: BBNX) closed at $25.04 in the last session, down -5.55% from day before closing price of $26.51. In other words, the price has decreased by -$5.55 from its previous closing price. On the day, 0.69 million shares were traded. BBNX stock price reached its highest trading level at $26.63 during the session, while it also had its lowest trading level at $24.33.
Ratios:
We take a closer look at BBNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 10.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 01, 2025, Goldman Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $26.Truist initiated its Buy rating on June 16, 2025, with a $26 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 31 ’25 when Lezack Adam sold 1,406 shares for $26.87 per share. The transaction valued at 37,780 led to the insider holds 9,841 shares of the business.
Palasis Maria sold 1,406 shares of BBNX for $37,834 on Oct 31 ’25. The Director now owns 9,841 shares after completing the transaction at $26.91 per share. On Oct 31 ’25, another insider, ADAM LEZACK, who serves as the Director of the company, bought 2,812 shares for $26.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 1102376832 and an Enterprise Value of 881376768. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.45 while its Price-to-Book (P/B) ratio in mrq is 3.74. Its current Enterprise Value per Revenue stands at 9.951 whereas that against EBITDA is -13.091.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $30.47, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is 11.15%, while the 200-Day Moving Average is calculated to be 43.47%.
Shares Statistics:
According to the various share statistics, BBNX traded on average about 807.29K shares per day over the past 3-months and 995870 shares per day over the past 10 days. A total of 43.99M shares are outstanding, with a floating share count of 33.17M. Insiders hold about 24.65% of the company’s shares, while institutions hold 90.96% stake in the company. Shares short for BBNX as of 1760486400 were 4169413 with a Short Ratio of 5.16, compared to 1757894400 on 3882499. Therefore, it implies a Short% of Shares Outstanding of 4169413 and a Short% of Float of 10.6800005.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Beta Bionics Inc (BBNX) in the stock market.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.34 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.64 and -$2.06 for the fiscal current year, implying an average EPS of -$1.94. EPS for the following year is -$1.66, with 6.0 analysts recommending between -$1.27 and -$2.0.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $28.9M. It ranges from a high estimate of $29.8M to a low estimate of $28M. As of. The current estimate, Beta Bionics Inc’s year-ago sales were $20.44MFor the next quarter, 10 analysts are estimating revenue of $27.56M. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $24.2M.
A total of 10 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $97.9M, while the lowest revenue estimate was $96.5M, resulting in an average revenue estimate of $97.13M. In the same quarter a year ago, actual revenue was $65.12MBased on 10 analysts’ estimates, the company’s revenue will be $132.17M in the next fiscal year. The high estimate is $143.98M and the low estimate is $121M.
